Alpha 2.0
Login Register
» Authors » Junichi Kurebayashi

Junichi Kurebayashi

Explore the profile of Junichi Kurebayashi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 98
Citations 878
Followers 0
Related Specialties
Oncology
Endocrinology
General Medicine
Top 10 Co-Authors
Hiroshi Sonoo
Katsuhiro Tanaka
Takuya Moriya
Yutaka Yamamoto
Tsunehisa Nomura
Naoki Kanomata
Masahiko Ikeda
Kazutaka Nakashima
Shinzaburo Noguchi
Masafumi Kurosumi
Published In
Breast Cancer
Gan To Kagaku Ryoho
Cancer Chemother Pharmacol
Int J Oncol
Surg Today
Affiliations
Soon will be listed here.
Recent Articles
1.
[Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase Ⅱ Trial]
Ogata R, Yamamoto Y, Jo A, Fukuma Y, Mikami T, Kawano S, et al.
Gan To Kagaku Ryoho . 2022 Jul; 49(6):677-682. PMID: 35799395
Clinical studies have confirmed that nab-paclitaxel(nab-PTX)therapy is effective and safe in patients with metastatic breast cancer. Neoadjuvant chemotherapy(NAC) with nab-PTX has resulted in a pathological complete response (pCR) rate of...
2.
A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response
Nomura T, Kurebayashi J, Moriya T, Saito W, Murata T, Yamamoto J, et al.
Anticancer Res . 2021 Dec; 41(12):6191-6197. PMID: 34848473
Background: Matrix-producing breast carcinoma (MPBC) is a very rare and usually aggressive triple-negative breast cancer. We successfully established a patient-derived orthotopic xenograft (PDOX) model from a patient with MPBC and...
3.
A case of human breast sparganosis diagnosed as Spirometra Type I by molecular analysis in Japan
Okino T, Yamasaki H, Yamamoto Y, Fukuma Y, Kurebayashi J, Sanuki F, et al.
Parasitol Int . 2021 May; 84:102383. PMID: 34044106
A 92-year-old Japanese woman presented with a mass in the left breast, and sparganosis was suspected by biopsy of the mass. The mass disappeared once, but it reappeared at the...
4.
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with...
Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, et al.
Breast Cancer . 2021 Feb; 28(3):684-697. PMID: 33638810
Background: Previously, we conducted the 5-year open-label, randomized controlled trial (RCT) of leuprorelin adjuvant therapy in post-operative premenopausal patients with endocrine-responsive breast cancer, which was a pilot study to investigate...
5.
Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions
Akahane T, Kanomata N, Harada O, Yamashita T, Kurebayashi J, Tanimoto A, et al.
BMC Cancer . 2020 Oct; 20(1):944. PMID: 33004031
Background: Next-generation sequencing (NGS) has shown that recurrent/metastatic breast cancer lesions may have additional genetic changes compared with the primary tumor. These additional changes may be related to tumor progression...
6.
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J
Breast Cancer . 2020 Aug; 28(1):206-215. PMID: 32860163
Background: Combined endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor has been indicated to improve not only progression-free survival, but also overall survival in patients with hormone receptor (HR)-positive,...
7.
Automated assessment of Ki-67 in breast cancer: the utility of digital image analysis using virtual triple staining and whole slide imaging
Hida A, Omanovic D, Pedersen L, Oshiro Y, Ogura T, Nomura T, et al.
Histopathology . 2020 Jun; 77(3):471-480. PMID: 32578891
Aims: Precise evaluation of proliferative activity is essential for the stratified treatment of luminal-type breast cancer (BC). Immunohistochemical staining of Ki-67 has been widely used to determine proliferative activity and...
8.
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model
Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, et al.
Anticancer Res . 2020 May; 40(5):2475-2479. PMID: 32366391
Background/aim: Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a...
9.
Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
Kishino E, Ogata R, Saitoh W, Koike Y, Ohta Y, Kanomata N, et al.
Breast Cancer . 2019 Dec; 27(3):415-425. PMID: 31823286
Background: A cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib, has been used to treat patients with estrogen receptor (ER)-positive (+) and human epidermal growth factor receptor (HER) 2-negative (-) advanced breast...
10.
Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors
Kanomata N, Yamaguchi R, Kurebayashi J, Moriya T
Med Mol Morphol . 2019 May; 53(1):15-20. PMID: 31139940
Pathological diagnosis of intraductal apocrine lesions can be challenging, because even benign apocrine lesions often show atypical cytology, and immunohistochemistry is of little assistance. A new diagnostic method for apocrine...